Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Alferon N Injection for HIV-infected patients makes progress

Feb. 26, 1998

Nucleoside with potent and selective anti-HIV and anti-HBV activity

Feb. 25, 1998

Quinolone HIV integrase inhibitors prepared at Warner-Lambert

Feb. 24, 1998

Controlled trial of peptide T for cognitive impairment in HIV-infected patients

Feb. 23, 1998

Nucleoside analogues from BioChem Therapeutic show potential for HIV/AIDS

Feb. 23, 1998

U.S. patent will issue covering Theratechnologies' AIDS gene therapy

Feb. 20, 1998

Transgenic production program begins for novel HIV therapeutic

Feb. 19, 1998

Novel imidazoles from Shionogi target lymph nodes

Feb. 19, 1998

Sea cucumber-based agent may increase well-being in HIV/AIDS patients

Feb. 19, 1998

Remune decreases levels of TNF-alpha in HIV-infected patients

Feb. 19, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...